Balmayor_2008_J.Mater.Sci.Mater.Med_19_1617

Reference

Title : A novel enzymatically-mediated drug delivery carrier for bone tissue engineering applications: combining biodegradable starch-based microparticles and differentiation agents - Balmayor_2008_J.Mater.Sci.Mater.Med_19_1617
Author(s) : Balmayor ER , Tuzlakoglu K , Marques AP , Azevedo HS , Reis RL
Ref : J Mater Sci Mater Med , 19 :1617 , 2008
Abstract :

In many biomedical applications, the performance of biomaterials depends largely on their degradation behavior. For instance, in drug delivery applications, the polymeric carrier should degrade under physiological conditions slowly releasing the encapsulated drug. The aim of this work was, therefore, to develop an enzymatic-mediated degradation carrier system for the delivery of differentiation agents to be used in bone tissue engineering applications. For that, a polymeric blend of starch with polycaprolactone (SPCL) was used to produce a microparticle carrier for the controlled release of dexamethasone (DEX). In order to investigate the effect of enzymes on the degradation behavior of the developed system and release profile of the encapsulated osteogenic agent (DEX), the microparticles were incubated in phosphate buffer solution in the presence of alpha-amylase and/or lipase enzymes (at physiological concentrations), at 37 degrees C for different periods of time. The degradation was followed by gravimetric measurements, scanning electron microscopy (SEM) and Fourier transformed infrared (FTIR) spectroscopy and the release of DEX was monitored by high performance liquid chromatography (HPLC). The developed microparticles were shown to be susceptible to enzymatic degradation, as observed by an increase in weight loss and porosity with degradation time when compared with control samples (incubation in buffer only). For longer degradation times, the diameter of the microparticles decreased significantly and a highly porous matrix was obtained. The in vitro release studies showed a sustained release pattern with 48% of the encapsulated drug being released for a period of 30 days. As the degradation proceeds, it is expected that the remaining encapsulated drug will be completely released as a consequence of an increasingly permeable matrix and faster diffusion of the drug. Cytocompatibility results indicated the possibility of the developed microparticles to be used as biomaterial due to their reduced cytotoxic effects.

PubMedSearch : Balmayor_2008_J.Mater.Sci.Mater.Med_19_1617
PubMedID: 18214645

Related information

Citations formats

Balmayor ER, Tuzlakoglu K, Marques AP, Azevedo HS, Reis RL (2008)
A novel enzymatically-mediated drug delivery carrier for bone tissue engineering applications: combining biodegradable starch-based microparticles and differentiation agents
J Mater Sci Mater Med 19 :1617

Balmayor ER, Tuzlakoglu K, Marques AP, Azevedo HS, Reis RL (2008)
J Mater Sci Mater Med 19 :1617